These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33486336)

  • 1. Drug prescription for attention deficit hyperactivity disorder drugs in pediatric outpatients: A retrospective survey of Japanese administrative data (2012-2018).
    Kikuchi D; Obara T; Tokunaga M; Shiozawa M; Takahashi A; Ito M; Hino H; Miura R; Hayakawa S; Watanabe Y
    Asian J Psychiatr; 2021 Mar; 57():102512. PubMed ID: 33486336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine.
    Shyu YC; Lee SY; Yuan SS; Yang CJ; Yang KC; Lee TL; Wang LJ
    Clin Ther; 2016 Mar; 38(3):595-602. PubMed ID: 26874787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients.
    Bushe C; Day K; Reed V; Karlsdotter K; Berggren L; Pitcher A; Televantou F; Haynes V
    J Psychopharmacol; 2016 May; 30(5):444-58. PubMed ID: 27005307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Prescriptions for Children With ADHD in Japan: A Study Based on Health Insurance Claims Data Between 2005 and 2015.
    Yoshida M; Obara T; Kikuchi S; Satoh M; Morikawa Y; Ooba N; Yamaguchi H; Mano N
    J Atten Disord; 2020 Jan; 24(2):175-191. PubMed ID: 31056996
    [No Abstract]   [Full Text] [Related]  

  • 6. Differential Treatment Effects of Methylphenidate and Atomoxetine on Executive Functions in Children with Attention-Deficit/Hyperactivity Disorder.
    Wu CS; Shang CY; Lin HY; Gau SS
    J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):187-196. PubMed ID: 33890819
    [No Abstract]   [Full Text] [Related]  

  • 7. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
    Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
    J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medications for attention-deficit/hyperactivity disorder in Japan: A retrospective cohort study of label compliance.
    Fife D; Voss EA; Hardin J; Rofael H; Solomon ID; Ryan PB; Stang P
    Neuropsychopharmacol Rep; 2021 Sep; 41(3):385-392. PubMed ID: 34180161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secular trends and regional variations in pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) among children and adolescents in Germany.
    Akmatov MK; Holstiege J; Bätzing J
    BMC Psychiatry; 2021 Aug; 21(1):405. PubMed ID: 34391396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B; Karakaya E; Oztop DB
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in attention-deficit/hyperactivity disorder drug consumption in children and adolescents in Slovenia from 2001 to 2012: a drug use study from a national perspective.
    Štuhec M; Locatelli I; Švab V
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):254-9. PubMed ID: 25803789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Efficacy of Methylphenidate and Atomoxetine on Emotional and Behavioral Problems in Youths with Attention-Deficit/Hyperactivity Disorder.
    Shih HH; Shang CY; Gau SS
    J Child Adolesc Psychopharmacol; 2019 Feb; 29(1):9-19. PubMed ID: 30457349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 10-year trend in drug prescriptions for attention-deficit/hyperactivity disorder (ADHD) in Germany.
    Grimmsmann T; Himmel W
    Eur J Clin Pharmacol; 2021 Jan; 77(1):107-115. PubMed ID: 32803292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006.
    van den Ban E; Souverein P; Swaab H; van Engeland H; Heerdink R; Egberts T
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):55-61. PubMed ID: 20166797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in Utilization Patterns among Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: a 36-Month Retrospective Study Using the Korean Health Insurance Review and Assessment Claims Database.
    Bhang SY; Hwang JW; Kwak YS; Joung YS; Lee S; Kim B; Sohn SH; Chung US; Yang J; Hong M; Bahn GH; Choi HY; Oh IH; Lee YJ
    J Korean Med Sci; 2016 Aug; 31(8):1284-91. PubMed ID: 27478341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of negative media publicity on attention-deficit/hyperactivity disorder medication in Taiwan.
    Wang LJ; Lee SY; Yuan SS; Yang CJ; Yang KC; Lee TL; Shyu YC
    Pharmacoepidemiol Drug Saf; 2016 Jan; 25(1):45-53. PubMed ID: 26549311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, incidence and persistence of ADHD drug use in Japan.
    Okumura Y; Usami M; Okada T; Saito T; Negoro H; Tsujii N; Fujita J; Iida J
    Epidemiol Psychiatr Sci; 2019 Dec; 28(6):692-696. PubMed ID: 29804548
    [No Abstract]   [Full Text] [Related]  

  • 20. Prescribing patterns for attention deficit hyperactivity disorder among children and adolescents in Taiwan from 2004 to 2017.
    Liao HC; Lin FJ; Hsu CN; Gau SS; Wang CC
    J Formos Med Assoc; 2023 Jun; 122(6):514-517. PubMed ID: 36931958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.